Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118127158> ?p ?o ?g. }
- W3118127158 endingPage "206" @default.
- W3118127158 startingPage "191" @default.
- W3118127158 abstract "Immunotherapies have shown remarkable success in the treatment of multiple cancer types; however, despite encouraging preclinical activity, registration trials of immunotherapy in prostate cancer have largely been unsuccessful. Sipuleucel-T remains the only approved immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer based on modest improvement in overall survival. This immune evasion in the case of prostate cancer has been attributed to tumor-intrinsic factors, an immunosuppressive tumor microenvironment, and host factors, which ultimately make it an inert ‘cold’ tumor. Recently, multiple approaches have been investigated to turn prostate cancer into a ‘hot’ tumor. Antibodies directed against programmed cell death protein 1 have a tumor agnostic approval for a small minority of patients with microsatellite instability-high or mismatch repair-deficient metastatic prostate cancer. Herein, we present an overview of the current immunotherapy landscape in metastatic castration-resistant prostate cancer with a focus on immune checkpoint inhibitors. We describe the results of clinical trials of immune checkpoint inhibitors in patients with metastatic castration-resistant prostate cancer; either as single agents or in combination with other checkpoint inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, tyrosine kinase inhibitors, novel hormonal therapies, chemotherapies, and radioligands. Finally, we review upcoming immunotherapies, including novel monoclonal antibodies, chimeric-antigen receptor (CAR) T cells, Bi-Specific T cell Engagers (BiTEs), therapies targeting the adenosine pathway, and other miscellaneous agents." @default.
- W3118127158 created "2021-01-05" @default.
- W3118127158 creator A5029298768 @default.
- W3118127158 creator A5034103357 @default.
- W3118127158 creator A5055269586 @default.
- W3118127158 creator A5080507578 @default.
- W3118127158 creator A5082022607 @default.
- W3118127158 date "2020-12-28" @default.
- W3118127158 modified "2023-10-18" @default.
- W3118127158 title "Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer" @default.
- W3118127158 cites W1066085235 @default.
- W3118127158 cites W1480342889 @default.
- W3118127158 cites W1542198162 @default.
- W3118127158 cites W1578291413 @default.
- W3118127158 cites W1849327862 @default.
- W3118127158 cites W1963569255 @default.
- W3118127158 cites W1972814015 @default.
- W3118127158 cites W1979371667 @default.
- W3118127158 cites W1979811833 @default.
- W3118127158 cites W1980241157 @default.
- W3118127158 cites W1990159077 @default.
- W3118127158 cites W1996956937 @default.
- W3118127158 cites W1999191024 @default.
- W3118127158 cites W2020022127 @default.
- W3118127158 cites W2024086357 @default.
- W3118127158 cites W2030908134 @default.
- W3118127158 cites W2037038224 @default.
- W3118127158 cites W2046427955 @default.
- W3118127158 cites W2052445509 @default.
- W3118127158 cites W2053554578 @default.
- W3118127158 cites W2064920472 @default.
- W3118127158 cites W2088571368 @default.
- W3118127158 cites W2092515164 @default.
- W3118127158 cites W2098574945 @default.
- W3118127158 cites W2098737737 @default.
- W3118127158 cites W2102979753 @default.
- W3118127158 cites W2103959341 @default.
- W3118127158 cites W2105400883 @default.
- W3118127158 cites W2112601576 @default.
- W3118127158 cites W2117089606 @default.
- W3118127158 cites W2120292596 @default.
- W3118127158 cites W2125821230 @default.
- W3118127158 cites W2127283640 @default.
- W3118127158 cites W2130011407 @default.
- W3118127158 cites W2130846254 @default.
- W3118127158 cites W2136280424 @default.
- W3118127158 cites W2142969867 @default.
- W3118127158 cites W2143772132 @default.
- W3118127158 cites W2148643283 @default.
- W3118127158 cites W2152337452 @default.
- W3118127158 cites W2153935963 @default.
- W3118127158 cites W2155846302 @default.
- W3118127158 cites W2161193168 @default.
- W3118127158 cites W2162640245 @default.
- W3118127158 cites W2166918329 @default.
- W3118127158 cites W2166970460 @default.
- W3118127158 cites W2169258216 @default.
- W3118127158 cites W2170069789 @default.
- W3118127158 cites W2172288218 @default.
- W3118127158 cites W2180120860 @default.
- W3118127158 cites W2237168462 @default.
- W3118127158 cites W2398722604 @default.
- W3118127158 cites W2462985846 @default.
- W3118127158 cites W2615520798 @default.
- W3118127158 cites W2752389930 @default.
- W3118127158 cites W2753432434 @default.
- W3118127158 cites W2792588868 @default.
- W3118127158 cites W2792937256 @default.
- W3118127158 cites W2797675588 @default.
- W3118127158 cites W2802394123 @default.
- W3118127158 cites W2806710293 @default.
- W3118127158 cites W2838357484 @default.
- W3118127158 cites W2883190832 @default.
- W3118127158 cites W2889640189 @default.
- W3118127158 cites W2902703786 @default.
- W3118127158 cites W2903718866 @default.
- W3118127158 cites W2908503672 @default.
- W3118127158 cites W2915177933 @default.
- W3118127158 cites W2921611058 @default.
- W3118127158 cites W2935069581 @default.
- W3118127158 cites W2947985252 @default.
- W3118127158 cites W2955376170 @default.
- W3118127158 cites W2961683572 @default.
- W3118127158 cites W2963342775 @default.
- W3118127158 cites W2969924938 @default.
- W3118127158 cites W2978008335 @default.
- W3118127158 cites W2979320780 @default.
- W3118127158 cites W2990771207 @default.
- W3118127158 cites W3006720751 @default.
- W3118127158 cites W3006844234 @default.
- W3118127158 cites W3007467190 @default.
- W3118127158 cites W3008844765 @default.
- W3118127158 cites W3021681456 @default.
- W3118127158 cites W3029590709 @default.
- W3118127158 cites W3031077210 @default.
- W3118127158 cites W3031255294 @default.
- W3118127158 cites W3031465744 @default.
- W3118127158 cites W3031516802 @default.